Company Overview

Nuo Therapeutics, Inc. (ticker: AURX) is a regenerative medicine and medical technology company historically focused on autologous cellular therapies and point-of-care biologics used in wound care and tissue regeneration. The company operated primarily within the healthcare and medical device sectors, with an emphasis on platelet-rich plasma and related blood-derived therapeutic technologies designed to support healing in chronic wounds and orthopedic applications. Public filings and historical market disclosures indicate that the company’s principal commercial platform centered on products derived from a patient’s own blood components for use by healthcare providers.

The company evolved from earlier regenerative medicine and biologics initiatives and was previously known as Cytomedix, Inc. before adopting the Nuo Therapeutics name. Its business strategy historically emphasized proprietary processing systems and clinical support for advanced wound care. Publicly available disclosures indicate that the company experienced periods of restructuring, financing activity, and operational realignment as it attempted to commercialize its technologies in competitive healthcare markets. Certain aspects of the company’s recent operating status and scale are difficult to verify consistently across public sources, and some data remains inconclusive based on available public disclosures.

Business Operations

Nuo Therapeutics historically generated revenue through the commercialization of regenerative therapy systems and related healthcare products, particularly within wound care and orthopedic treatment settings. Its principal operating activities were associated with the commercialization of the Aurix System, an autologous platelet-rich plasma therapy platform intended for chronic wound management. The company’s operations involved supplying processing kits, clinical support, and related services to healthcare providers and treatment centers. Historical filings indicate that the company’s commercial footprint was concentrated primarily in the United States healthcare market.

The company’s operational model relied on proprietary technologies associated with blood separation and platelet concentration processes used at the point of care. Public disclosures also referenced relationships with healthcare providers, reimbursement-related initiatives, and distribution activities connected to wound care clinics and hospitals. While historical SEC filings referenced subsidiaries and intellectual property assets associated with regenerative medicine technologies, publicly available information on currently active subsidiaries, joint ventures, or material strategic partnerships is limited and in some cases inconclusive based on available public sources.

Strategic Position & Investments

Nuo Therapeutics historically positioned itself within the regenerative medicine and chronic wound care market, targeting areas where autologous biologic therapies could potentially improve healing outcomes and reduce treatment duration. Strategic initiatives described in public filings included efforts to expand clinical adoption of the Aurix System, pursue reimbursement coverage opportunities, and strengthen physician utilization within specialized wound care networks. The company also emphasized the use of patient-derived biologics as an alternative or complement to traditional wound management approaches.

Historically, the company pursued investments in intellectual property, commercialization infrastructure, and clinical validation activities related to regenerative therapies. Public disclosures over time also reflected restructuring measures and financing efforts intended to sustain operations and support commercialization. Information regarding significant recent acquisitions, portfolio investments, or active emerging technology initiatives is limited in publicly available records, and several operational details appear inactive or unclear based on more recent market data and corporate reporting availability.

Geographic Footprint

Nuo Therapeutics’ operational presence was primarily concentrated in the United States, where the company focused on healthcare providers, wound care clinics, and hospital systems utilizing regenerative treatment technologies. The company was headquartered in the United States, with historical filings identifying operations centered around domestic commercialization and clinical support activities rather than broad multinational manufacturing or distribution infrastructure.

Publicly available information does not indicate a substantial direct operating footprint across multiple continents comparable to larger global medical device companies. International commercial penetration, overseas subsidiaries, and material foreign investment activity are not prominently documented in available public filings. Data regarding current international operations is inconclusive based on available public sources.

Leadership & Governance

Nuo Therapeutics’ leadership historically included executives with backgrounds in healthcare commercialization, biotechnology, regenerative medicine, and medical devices. The company’s governance approach, as reflected in historical SEC filings, focused on advancing commercialization opportunities for autologous biologic technologies while managing financing and operational restructuring challenges associated with smaller publicly traded healthcare companies.

Key historical executives and leadership figures identified in public filings include:

• David J. Gelbard – Chairman and executive leadership roles historically associated with strategic direction and financing activities
• Robert J. Brown – Former executive leadership roles connected to commercialization and corporate operations
• Joseph A. Sardano – Former executive leadership roles associated with operational management and regenerative medicine strategy

Recent executive and governance information is limited in consistency across publicly accessible records, and some current leadership details are inconclusive based on available public sources and filing activity.